
WHAT IS CLAIMED IS:

1. A compound of Formula I:



(I)

or pharmaceutically acceptable salts, or hydrates thereof, wherein

R^{1a} and R^{1b} are each independently selected from the group consisting of H and CH_3;

R^{2a} selected from the group consisting of H and F; and

R^{2d} is selected from the group consisting of H, C_{1-4} alkoxy and C_{1-4} haloalkoxy,

provided that the compound of Formula I is not 2-(4-amino-3-(1H-imidazol-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-1-(4-(4-chloro-3-methoxyphenyl)piperazin-1-yl)ethanone.

2. The compound of claim 1, wherein R^{2a} is H.


3. The compound of claim 1, wherein R^{1a} and R^{1b} are each H.

4. The compound of claim 1, wherein R^{1b} is methyl and R^{1a} is H.


5. The compound of claim 1, wherein R^{1a} and R^{1b} are each CH_3.

6. The compound of claim 1, wherein R^{2a} is hydrogen and R^{2d} is selected from the group consisting of methoxy, ethoxy and trifluoromethoxy.

7. The compound of claim 1, wherein said compound is of Formula Ia or Ib.




Ia




Ib

wherein R^{2a} is selected from the group consisting of H and F; and R^{2d} is selected from the group consisting of methoxy, ethoxy and trifluoromethoxy.


8. The compound of claim 1, wherein said compound is selected from the group consisting of:




,



,




and





.


9. The compound of claim 1, wherein said compound is selected from the group consisting of:





.












and



10. The compound of claim 1, wherein said salt form is a hydrochloride salt form.

11. A compound selected from the group consisting of:

(S)-2-(4-amino-3-(1H-imidazol-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-1-(4-(4-chloro-2-fluoro-5-methoxyphenyl)-2-methylpiperazin-1-yl)ethanone;

(S)-2-(4-amino-3-(1H-imidazol-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-1-(4-(4-chloro-2-fluorophenyl)-2-methylpiperazin-1-yl)ethanone;

2-(4-amino-3-(1H-imidazol-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-1-(4-(4-chloro-2-fluoro-5-methoxyphenyl)piperazin-1-yl)ethanone;

2-(4-amino-3-(1H-imidazol-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-1-(4-(4-chloro-2-fluoro-5-methoxyphenyl)piperazin-1-yl)ethanone;

(S)-2-(4-amino-3-(1H-imidazol-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-1-(4-(4-chloro-3-methoxyphenyl)-2-methylpiperazin-1-yl)ethanone;

2-(4-amino-3-(1H-imidazol-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-1-(4-(4-chloro-3-ethoxyphenyl)piperazin-1-yl)ethanone;

(S)-2-(4-amino-3-(1H-imidazol-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-1-(4-(4-chlorophenyl)-2-methylpiperazin-1-yl)ethanone;

2-(4-amino-3-(1H-imidazol-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-1-(4-(4-chlorophenyl)piperazin-1-yl)ethanone;

2-(4-amino-3-(1H-imidazol-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-1-(4-(4-chloro-3-methoxyphenyl)-2,2-dimethylpiperazin-1-yl)ethanone;

(S)-2-(4-amino-3-(1H-imidazol-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-1-(4-(4-chloro-3-ethoxyphenyl)-2-methylpiperazin-1-yl)ethanone; and

2-(4-amino-3-(1H-imidazol-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-1-(4-(4-chloro-3-(trifluoromethoxy)phenyl)piperazin-1-yl)ethanone.

12. A pharmaceutical composition for comprising a compound of claim 1, and a pharmaceutically acceptable excipient or carrier.

13. The use of a compound of any of claim 1-11 in the manufacture of a medicament for the treatment of CCR1-mediated diseases or conditions.

14. A use in accordance with claim 13, wherein said CCR1-mediated disease or condition is an inflammatory condition.

15. A use in accordance with claim 13, wherein said CCR1-mediated disease or condition is an immunoregulatory disorder.

16. A use in accordance with claim 13, wherein said CCR1-mediated disease or condition is slected from the grou consisting of osteoarthritic disease, multiple myeloma, rheumatoid arthritis, multiple sclerosis, transplant rejection, restenosis, dermatitis, eczema, urticaria, vasculitis, inflammatory bowel disease, food allergy, asthma, Alzheimer's disease, Parkinson's disease, psoriasis, lupus erythematosus, osteoarthritis, stroke, restenosis or encephalomyelitis.


17. A use in accordance with claim 13, wherein said CCR1 mediated disease or condition is selected from the group consisting of osteoarthritic disease, multiple myeloma, rheumatorid arthritis and transplant rejection.

18. A use in accordance with claim 13, wherein said medicament is manufactured for oral, parenteral, rectal, transdermal, sublingual, nasal or topical administration

19. A use in accordance with claim 13, wherein said medicament is manufactured for administration in combination with an anti-inflammator agent, analgesic agent, an anti-proliferative agent, a metabolic inhibitor, a leukocyte migration inhibitor or an immunomodulatory.

Claims:

1. A compound of Formula I:



(I)

or pharmaceutically acceptable salts, or hydrates thereof, wherein

R^{1a} and R^{1b} are each independently selected from the group consisting of H and CH_3;

R^{2a} selected from the group consisting of H and F; and

R^{2d} is selected from the group consisting of H, C_{1-4} alkoxy and C_{1-4} haloalkoxy,

provided that the compound of Formula I is not 2-(4-amino-3-(1H-imidazol-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-1-(4-(4-chloro-3-methoxyphenyl)piperazin-1-yl)ethanone.

2. The compound of claim 1, wherein R^{2a} is H.


3. The compound of claim 1, wherein R^{1a} and R^{1b} are each H.


4. The compound of claim 1, wherein R^{1b} is methyl and R^{1a} is H.

5. The compound of claim 1, wherein R^{1a} and R^{1b} are each CH_3.

6. The compound of claim 1, wherein R^{2a} is hydrogen and R^{2d} is selected from the group consisting of methoxy, ethoxy and trifluoromethoxy.

7. The compound of claim 1, wherein said compound is of Formula Ia or Ib.










Ia Ib


wherein R^{2a} is selected from the group consisting of H and F; and R^{2d} is selected from the group consisting of methoxy, ethoxy and trifluoromethoxy.


8. The compound of claim 1, wherein said compound is selected from the group consisting of:



,

,

and

.


9. The compound of claim 1, wherein said compound is selected from the group consisting of:















and



10. The compound of claim **1**, wherein said salt form is a hydrochloride salt form.

11. A compound selected from the group consisting of:

(S)-2-(4-amino-3-(1H-imidazol-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-1-(4-(4-chloro-2-fluoro-5-methoxyphenyl)-2-methylpiperazin-1-yl)ethanone;

(S)-2-(4-amino-3-(1H-imidazol-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-1-(4-(4-chloro-2-fluorophenyl)-2-methylpiperazin-1-yl)ethanone;

2-(4-amino-3-(1H-imidazol-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-1-(4-(4-chloro-2-fluoro-5-methoxyphenyl)piperazin-1-yl)ethanone;

2-(4-amino-3-(1H-imidazol-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-1-(4-(4-chloro-2-fluoro-5-methoxyphenyl)piperazin-1-yl)ethanone;

(S)-2-(4-amino-3-(1H-imidazol-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-1-(4-(4-chloro-3-methoxyphenyl)-2-methylpiperazin-1-yl)ethanone;

2-(4-amino-3-(1H-imidazol-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-1-(4-(4-chloro-3-ethoxyphenyl)piperazin-1-yl)ethanone;

(S)-2-(4-amino-3-(1H-imidazol-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-1-(4-(4-chlorophenyl)-2-methylpiperazin-1-yl)ethanone;

2-(4-amino-3-(1H-imidazol-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-1-(4-(4-chlorophenyl)piperazin-1-yl)ethanone;

2-(4-amino-3-(1H-imidazol-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-1-(4-(4-chloro-3-methoxyphenyl)-2,2-dimethylpiperazin-1-yl)ethanone;

(S)-2-(4-amino-3-(1H-imidazol-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-1-(4-(4-chloro-3-ethoxyphenyl)-2-methylpiperazin-1-yl)ethanone; and

2-(4-amino-3-(1H-imidazol-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-1-(4-(4-chloro-3-(trifluoromethoxy)phenyl)piperazin-1-yl)ethanone.

12. A pharmaceutical composition for comprising a compound of claim **1**, and a pharmaceutically acceptable excipient or carrier.

13. The use of a compound of any of claim **1-11** in the manufacture of a medicament for the treatment of CCR1-mediated diseases or conditions, wherein said CCR1-mediated disease or condition is an inflammatory condition or an immunoregulatory disorder.

14. A use in accordance with claim **13**, wherein said CCR1-mediated disease or condition is selected from the group consisting of osteoarthritic disease, multiple myeloma, rheumatoid arthritis, multiple sclerosis, transplant rejection, restenosis, dermatitis, eczema, urticaria, vasculitis, inflammatory bowel disease, food allergy, asthma, Alzheimer's disease, Parkinson's disease, psoriasis, lupus erythematosus, osteoarthritis, stroke, restenosis or encephalomyelitis.

15. A use in accordance with claim **13**, wherein said CCR1 mediated disease or condition is selected from the group consisting of osteoarthritic disease, multiple myeloma, rheumatorid arthritis and transplant rejection.

16. A use in accordance with claim **13**, wherein said medicament is manufactured for oral, parenteral, rectal, transdermal, sublingual, nasal or topical administration

17. A use in accordance with claim **13**, wherein said medicament is manufactured for administration in combination with an anti-inflammatory agent, analgesic agent, an anti-proliferative agent, a metabolic inhibitor, a leukocyte migration inhibitor or an immunomodulatory.